Topical Ruxolitinib Reduced GVHD Skin Lesion Surface Area
A clinical trial found that applying the cream twice daily helped some transplant patients reduce affected skin areas.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you believe new medical treatments should be preferred over traditional standard care methods?
Researchers have found that applying a 1.5% ruxolitinib cream twice daily significantly reduces the surface area of skin lesions in patients with chronic graft-versus-host disease. This condition occurs in about 50% of people who receive an allogeneic hematopoietic stem cell transplant.
Why it matters
Managing skin lesions is a significant challenge for transplant patients, as standard treatments often provide inconsistent results. This study offers a potential new topical strategy for those dealing with the long-term effects of chronic graft-versus-host disease.
In a clinical trial of 24 participants, topical 1.5% ruxolitinib cream reduced mean affected skin surface area from 14.3% to 6.2% over 28 days. This outperformed the control group, which saw a reduction from 14.5% to 10.4%.
The players
Cornell University
The academic institution where the research team conducted this study on graft-versus-host disease treatments.
The details
Ruxolitinib acts as a Janus kinase 1 and 2 inhibitor, which helps to modulate the inflammatory immune response driving the skin symptoms of graft-versus-host disease. By applying the cream directly to the skin twice daily, researchers aimed to target the localized inflammatory pathways without the systemic exposure associated with oral medications.
Timeline
Participants applied the cream twice daily for a period of 28 days.
Health Landscape
The research on topical ruxolitinib marks a departure from the current standard of care for chronic graft-versus-host disease, which has historically relied on systemic therapies with inconsistent outcomes. This study highlights a growing focus on localized, targeted therapies for dermatological complications of transplants.
Patients experiencing chronic graft-versus-host disease should discuss the potential for topical therapies with their oncology or dermatology care team. Because this study involved a limited number of participants, talk to your physician about whether your specific skin symptoms might be candidates for this approach.
The takeaway
This study demonstrates that topical Janus kinase inhibition may reduce skin lesion surface area in graft-versus-host disease patients without reported severe adverse effects. Patients should consult their care team to review the latest clinical options for localized symptom management.
Further reading
For more information on managing the complex symptoms associated with treatment, visit our section on Cancer.
Live Poll
Do you believe new medical treatments should be preferred over traditional standard care methods?
